Black Diamond Reports 86% Brain Response Rate, Maps Phase 3 Plan
Updated Phase 2 data showed an 86% CNS response rate in evaluable patients with untreated brain metastases, while FDA feedback shaped a planned Phase 3 trial.
Makkler Newsroom · Nov 10, 04:37 PM · 1 min read
